The European Journal of Health Economics

2002 - 2025

Current editor(s): J.-M.G.v.d. Schulenburg

From:
Springer
Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ)
Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla (sonal.shukla@springer.com) and Springer Nature Abstracting and Indexing (indexing@springernature.com).

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 19, issue 9, 2018

What should we know about the person behind a TTO? pp. 1207-1211

Floortje Nooten, Jan Busschbach, Michel Agthoven, Job Exel and Werner Brouwer

Preferences for home- and community-based long-term care services in Germany: a discrete choice experiment pp. 1213-1223

T. Lehnert, O. H. Günther, A. Hajek, S. G. Riedel-Heller and H. H. König

Some adjustments to the human capital and the friction cost methods pp. 1225-1228

Antonis Targoutzidis

Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach pp. 1229-1242

Ann-Kathrin Richter, Ludger Klimek, Hans F. Merk, Norbert Mülleneisen, Harald Renz, Wolfgang Wehrmann, Thomas Werfel, Eckard Hamelmann, Uwe Siebert, Gaby Sroczynski, Juergen Wasem and Janine Biermann-Stallwitz

The economic impact of multiple sclerosis to the patients and their families in Norway pp. 1243-1257

B. Svendsen, N. Grytten, L. Bø, H. Aarseth, T. Smedal and K-M. Myhr

Tackling the chronic disease burden: are there co-benefits from climate policy measures? pp. 1259-1283

Désirée Vandenberghe and Johan Albrecht

Health inequality indices and exogenous risk factors: an illustration on Luxembourgish workers pp. 1285-1301

Stéphane Mussard, Maria Pi Alperin and Véronique Thireau

Cost–utility analysis of an intervention designed to reduce the critical handling error of insufficient inspiratory effort pp. 1303-1318

Rebecca Forster, Aran Ratcliffe, Megan Lewis, Amy Crossley, Julio López Bastida and William C. N. Dunlop

Cost-effectiveness of enhancing a Quit-and-Win smoking cessation program for college students pp. 1319-1333

Jonah Popp, John A. Nyman, Xianghua Luo, Jill Bengtson, Katherine Lust, Lawrence An, Jasjit S. Ahluwalia and Janet L. Thomas

People’s perception and cost-effectiveness of home confinement during an influenza pandemic: evidence from the French case pp. 1335-1350

Caroline Orset

Examining unpriced risk heterogeneity in the Dutch health insurance market pp. 1351-1363

Cees Withagen, R. C. Kleef and F. Eijkenaar

Economic evaluation of Zepatier for the management of HCV in the Italian scenario pp. 1365-1374

F. R. Rolli, M. Ruggeri, F. Kheiraoui, Carlo Drago, M. Basile, C. Favaretti and A. Cicchetti

Volume 19, issue 8, 2018

Pharmaceutical pricing conundrum: time to get rid of it? pp. 1035-1038

Livio Garattini and Anna Padula

Health polarization and inequalities across Europe: an empirical approach pp. 1039-1051

Marta Pascual, David Cantarero and Paloma Lanza

How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity pp. 1053-1066

Matthew Quaife, Fern Terris-Prestholt, Gian Luca Di Tanna and Peter Vickerman

Testing the Grossman model of medical spending determinants with macroeconomic panel data pp. 1067-1086

Jochen Hartwig and Jan-Egbert Sturm

Market structure and competition in the healthcare industry pp. 1087-1110

Martin Lábaj, Peter Silanič, Christoph Weiss and Biliana Yontcheva

The earnings and employment losses before entering the disability system pp. 1111-1128

María Cervini-Plá and Judit Vall Castello

Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records pp. 1129-1136

Marc Casajuana, Maria Giner-Soriano, Albert Roso-Llorach, Cristina Vedia, Concepció Violan and Rosa Morros

Unobserved heterogeneity in work absence pp. 1137-1148

María José Suárez and Cristina Muñiz

How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts pp. 1149-1161

Simon Wieser, Marco Riguzzi, Mark Pletscher, Carola A. Huber, Harry Telser and Matthias Schwenkglenks

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England pp. 1163-1172

Yang Meng, Nadine Hertel, John Ellis, Edith Morais, Helen Johnson, Zoe Philips, Neil Roskell, Andrew Walker and Dawn Lee

The impact of health on wages: evidence for Europe pp. 1173-1187

Ana Rodriguez-Alvarez and César Rodriguez-Gutierrez

Does freedom make a difference? pp. 1189-1205

Philippe Tessier and Josselin Thuilliez

Volume 19, issue 7, 2018

EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data? pp. 905-907

F. Antoñanzas, C. A. Juárez-Castelló and R. Rodríguez-Ibeas

The effectiveness and cost-effectiveness of plant sterol or stanol-enriched functional foods as a primary prevention strategy for people with cardiovascular disease risk in England: a modeling study pp. 909-922

Wei Yang, Heather Gage, Daniel Jackson and Monique Raats

Health care service utilization of documented and undocumented hired farmworkers in the U.S pp. 923-934

Tianyuan Luo and Cesar Escalante

Ebola in the Netherlands, 2014–2015: costs of preparedness and response pp. 935-943

Anita W. M. Suijkerbuijk, Corien M. Swaan, Marie-Josee J. Mangen, Johan J. Polder, Aura Timen and Wilhelmina L. M. Ruijs

The impact of waiting for intervention on costs and effectiveness: the case of transcatheter aortic valve replacement pp. 945-956

Aida Ribera, John Slof, Ignacio Ferreira-González, Vicente Serra, Bruno García-del Blanco, Purificació Cascant, Rut Andrea, Carlos Falces, Enrique Gutiérrez, Raquel del Valle-Fernández, César Morís- de laTassa, Pedro Mota, Juan Francisco Oteo, Pilar Tornos and David García-Dorado

Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation pp. 957-965

Maartje S. Jacobs, Lisa A. Jong, Maarten J. Postma, Robert G. Tieleman and Marinus Hulst

The effect of online gambling on gambling problems and resulting economic health costs in Germany pp. 967-978

Tobias Effertz, Anja Bischof, Hans-Jürgen Rumpf, Christian Meyer and Ulrich John

Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review pp. 979-991

Lidia García-Pérez, Renata Linertová, Margarita Álvarez- de-la-Rosa, Juan Carlos Bayón, Iñaki Imaz-Iglesia, Jorge Ferrer-Rodríguez and Pedro Serrano-Aguilar

Consensus-based cross-European recommendations for the identification, measurement and valuation of costs in health economic evaluations: a European Delphi study pp. 993-1008

Lisanne I. Lier, Judith E. Bosmans, Hein P. J. Hout, Lidwine B. Mokkink, Wilbert B. Hout, G. Ardine Wit, Carmen D. Dirksen, Henk L. G. R. Nies, Cees M. P. M. Hertogh and Henriëtte G. Roest

Assessing the opportunity costs of patients with multidrug-resistant organisms in hospitals pp. 1009-1017

Claudia Hübner, Walter Ried and Steffen Flessa

Threshold analysis in the presence of both the diagnostic and the therapeutic risk pp. 1019-1026

Stefan Felder and Thomas Mayrhofer

Impact of specialist rehabilitation services on hospital length of stay and associated costs pp. 1027-1034

A. Duarte, C. Bojke, W. Cayton, A. Salawu, B. Case, L. Bojke and G. Richardson

Volume 19, issue 6, 2018

Does the approach to economic evaluation in health care depend on culture, values, and institutional context? pp. 769-774

Aleksandra Torbica, Rosanna Tarricone and Michael Drummond

The impact of copayments on mental healthcare utilization: a natural experiment pp. 775-784

Timo R. Lambregts and René C. J. A. Vliet

Uncontrolled diabetes and health care utilisation: panel data evidence from Spain pp. 785-795

Joan Gil, Antoni Sicras-Mainar and Eugenio Zucchelli

Does the use of the proportional shortfall help align the prioritisation of health services with public preferences? pp. 797-806

Jeff Richardson, Angelo Iezzi, Aimee Maxwell and Gang Chen

Measuring the end-of-life premium in cancer using individual ex ante willingness to pay pp. 807-820

S. Olofsson, Ulf-G. Gerdtham, Lars Hultkrantz and U. Persson

Guidelines versus reality: is coronary stent application in three-vessel disease standard or the exception? pp. 821-830

Roland Linder, J. Zeidler, Florian Verheyen, J.-M. Graf Schulenburg, A. Haverich and T. Schilling

Determinants of health care costs in the senior elderly: age, comorbidity, impairment, or proximity to death? pp. 831-842

Nisha C. Hazra, Caroline Rudisill and Martin C. Gulliford

Predicting medical practices using various risk attitude measures pp. 843-860

Sophie Massin, Antoine Nebout and Bruno Ventelou

A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy pp. 861-870

Ben F. M. Wijnen, Iris Mosweu, Marian H. J. M. Majoie, Leone Ridsdale, Reina J. A. Kinderen, Silvia M. A. A. Evers and Paul McCrone

Estimating a constant WTP for a QALY—a mission impossible? pp. 871-880

Björn Sund and Mikael Svensson

Experience-based utility and own health state valuation for a health state classification system: why and how to do it pp. 881-891

John Brazier, Donna Rowen, Milad Karimi, Tessa Peasgood, Aki Tsuchiya and Julie Ratcliffe

Cost–utility and cost-effectiveness of physical exercise during adjuvant chemotherapy pp. 893-904

Hanna Waart, Johanna M. Dongen, Wim H. Harten, Martijn M. Stuiver, Rosalie Huijsmans, Jeannette A. J. H. Hellendoorn- van Vreeswijk, Gabe S. Sonke and Neil K. Aaronson

Volume 19, issue 5, 2018

Patient empowerment in Europe: is no further research needed? pp. 637-640

Livio Garattini and Anna Padula

Health-related quality of life associated with bullying and aggression: a cross-sectional study in English secondary schools pp. 641-651

Catherine Fantaguzzi, Elizabeth Allen, Alec Miners, Deborah Christie, Charles Opondo, Zia Sadique, Adam Fletcher, Richard Grieve, Chris Bonell, Russell M. Viner and Rosa Legood

Estimating an exchange rate between the EQ-5D-3L and ASCOT pp. 653-661

Katherine Stevens, John Brazier and Donna Rowen

Choice of reserve capacity by hospitals: a problem for prospective payment pp. 663-673

Philippe K. Widmer, Maria Trottmann and Peter Zweifel

Chilean population norms derived from the health-related quality of Life SF-6D pp. 675-686

Miguel A. Garcia-Gordillo, Daniel Collado-Mateo, Pedro R. Olivares and José C. Adsuar

Ageing, health status and coverage rate effects on community prescription costs in Ireland pp. 687-695

Martin Kenneally and Brenda Lynch

Public acceptability of financial incentives to reward pregnant smokers who quit smoking: a United Kingdom–France comparison pp. 697-708

Noémi Berlin, Léontine Goldzahl, Linda Bauld, Pat Hoddinott and Ivan Berlin

Investigating the relationship between costs and outcomes for English mental health providers: a bi-variate multi-level regression analysis pp. 709-718

Valerie Moran and Rowena Jacobs

The relationship between diabetes, diabetes-related complications and productive activities among older Europeans pp. 719-734

B. Rodriguez-Sanchez, R. J. M. Alessie, T. L. Feenstra and Viola Angelini

Cost analysis of colorectal cancer screening with CT colonography in Italy pp. 735-746

Paola Mantellini, Giuseppe Lippi, Lapo Sali, Grazia Grazzini, Silvia Delsanto, Beatrice Mallardi, Massimo Falchini, Guido Castiglione, Francesca Maria Carozzi, Mario Mascalchi, Stefano Milani, Leonardo Ventura and Marco Zappa

Smoking, health-related quality of life and economic evaluation pp. 747-756

Ángel López-Nicolás, Marta Trapero-Bertran and Celia Muñoz

Can premium differentiation counteract adverse selection in the Dutch supplementary health insurance? A simulation study pp. 757-768

K. P. M. Winssen, R. C. Kleef and W. P. M. M. Ven

Volume 19, issue 4, 2018

How can dental insurance be optimized? pp. 483-487

Piet Calcoen and Wynand P. M. M. van de Ven

Incorporating equity in economic evaluations: a multi-attribute equity state approach pp. 489-498

Jeff Round and Mike Paulden

Primary care supply and quality of care in England pp. 499-519

Laura Vallejo-Torres and Stephen Morris

Determinants of catastrophic health expenditure in Nigeria pp. 521-532

Bolaji Samson Aregbeshola and Samina Mohsin Khan

Costs associated with community acquired pneumonia in France pp. 533-544

Grèce Saba, Luiz Andrade, Jacques Gaillat, Pierre Bonnin, Christian Chidiac, Hajnal-Gabriela Illes, Henri Laurichesse, Jonathan Messika, Jean-Damien Ricard, Bruno Detournay, Patrick Petitpretz and Gérard Pouvourville

Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan pp. 545-555

Shota Saito, Motoi Azumi, Yusuke Muneoka, Katsuhiko Nishino, Takashi Ishikawa, Yuichi Sato, Shuji Terai and Kouhei Akazawa

What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews pp. 557-570

Aureliano Paolo Finch, John Edward Brazier and Clara Mukuria

Introduction of therapeutic reference pricing in Slovenia and its economic consequences pp. 571-584

Nika Marđetko and Mitja Kos

The financial performance of the health care industry: a global, regional and industry specific empirical investigation pp. 585-594

Gregor Dorfleitner and Felix Rößle

Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment pp. 595-605

Amanda Cole, Koonal Shah, Brendan Mulhern, Yan Feng and Nancy Devlin

Autonomy and performance in the public sector: the experience of English NHS hospitals pp. 607-626

Rossella Verzulli, Rowena Jacobs and Maria Goddard

Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation pp. 627-636

Santiago Grau, Rafael Cámara, Manuel Jurado, Jaime Sanz, Belén Aragón and Irmina Gozalbo

Volume 19, issue 3, 2018

The triple challenge of mental health pp. 309-313

Peter Zweifel

Emotions and scope effects in the monetary valuation of health pp. 315-325

María V. Avilés Blanco, Raúl Brey, Jorge Araña and Jose-Luis Pinto-Prades

Economic and public health consequences of delayed access to medical care for migrants living with HIV in France pp. 327-340

Marlène Guillon, Michel Celse and Pierre Geoffard

Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation pp. 341-353

Dirk Müller, Marion Danner, Kerstin Rhiem, Björn Stollenwerk, Christoph Engel, Linda Rasche, Lisa Borsi, Rita Schmutzler and Stephanie Stock

The effectiveness of a population-based skin cancer screening program: evidence from Germany pp. 355-367

Micha Kaiser, Jörg Schiller and Christopher Schreckenberger

Does socioeconomic status affect lengthy wait time in Canada? Evidence from Canadian Community Health Surveys pp. 369-383

Mohammad Hajizadeh

Hospital heterogeneity: what drives the quality of health care pp. 385-408

Manhal Ali, Reza Salehnejad and Mohaimen Mansur

Burden of suicide in Poland in 2012: how could it be measured and how big is it? pp. 409-417

Katarzyna Orlewska and Ewa Orlewska

Using compensating variation to measure the costs of child disability in the UK pp. 419-433

Mariya Melnychuk, Francesca Solmi and Stephen Morris

Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age pp. 435-446

Hanna Gyllensten, Michael Wiberg, Kristina Alexanderson, Anders Norlund, Emilie Friberg, Jan Hillert, Olivia Ernstsson and Petter Tinghög

Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis pp. 447-462

Sofia Löfvendahl, Anna Jöud, Ingemar F. Petersson, Elke Theander, Åke Svensson and Katarina Steen Carlsson

The socio-economic impact of work disability due to inflammatory bowel disease in Brazil pp. 463-470

Renata S. B. Fróes, Ana Teresa Pugas Carvalho, Antonio Jose V. Carneiro, Adriana Maria Hilu Barros Moreira, Jessica P. L. Moreira, Ronir R. Luiz and Heitor S. de Souza

Comment on “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany” pp. 471-472

Afschin Gandjour

Authors’ reply to Gandjour: “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany” pp. 473-481

Alexander Kuhlmann and J.-Matthias Graf Schulenburg

Volume 19, issue 2, 2018

The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges pp. 173-175

Salah Ghabri and Josephine Mauskopf

A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set pp. 177-187

Gareth Thomas

The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach pp. 189-201

Grégoire Lagasnerie, Anne-Sophie Aguadé, Pierre Denis, Anne Fagot-Campagna and Christelle Gastaldi-Menager

Improving risk equalization using information on physiotherapy diagnoses pp. 203-211

Frank Eijkenaar and René C. J. A. Vliet

The impact of physician-level drug budgets on prescribing behavior pp. 213-222

Katharina Elisabeth Fischer, Taika Koch, Karel Kostev and Tom Stargardt

The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany pp. 223-228

Klaus Kaier, Holger Reinecke, Huseyin Naci, Lutz Frankenstein, Martin Bode, Werner Vach, Philip Hehn, Andreas Zirlik, Manfred Zehender and Jochen Reinöhl

Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom pp. 229-240

Michele R. Wilson, Annika Bergman, Helene Chevrou-Severac, Ross Selby, Michael Smyth and Matthew C. Kerrigan

Systematic review of model-based economic evaluations of heart valve implantations pp. 241-255

Simone A. Huygens, Johanna. J. M. Takkenberg and Maureen P. M. H. Rutten- van Mölken

Association between cultural distance and migrant self-rated health pp. 257-266

Jens Detollenaere, Stijn Baert and Sara Willems

Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies pp. 267-275

Erik Nord

New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year pp. 277-291

Arthur Attema, Marieke Krol, Job Exel and Werner Brouwer

Do healthcare tax credits help poor-health individuals on low incomes? pp. 293-307

Cinzia Di Novi, Anna Marenzi and Dino Rizzi

Volume 19, issue 1, 2018

Competition in pharmaceuticals: more product- than price-oriented? pp. 1-4

Livio Garattini and Anna Padula

Competition and quality indicators in the health care sector: empirical evidence from the Dutch hospital sector pp. 5-19

R. R. Croes, Y. J. F. M. Krabbe-Alkemade and M. C. Mikkers

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK pp. 21-35

Evelina A. Zimovetz, Alain Joseph, Rajeev Ayyagari and Josephine A. Mauskopf

Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy pp. 37-44

Umberto Restelli, Alfredo Alberti, Adriano Lazzarin, Marzia Bonfanti, Carmela Nappi and Davide Croce

Investigating social inequalities in older adults’ dentition and the role of dental service use in 14 European countries pp. 45-57

Jing Shen and Stefan Listl

Good jobs, good pay, better health? The effects of job quality on health among older European workers pp. 59-73

Golo Henseke

A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations pp. 75-86

Felix Achana, Stavros Petrou, Kamran Khan, Amadou Gaye and Neena Modi

Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial pp. 87-102

Bernhard Michalowsky, Steffen Flessa, Tilly Eichler, Johannes Hertel, Adina Dreier, Ina Zwingmann, Diana Wucherer, Henriette Rau, Jochen René Thyrian and Wolfgang Hoffmann

A “healthy immigrant effect” or a “sick immigrant effect”? Selection and policies matter pp. 103-121

Amelie Constant, Teresa García-Muñoz, Shoshana Neuman and Tzahi Neuman

Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries pp. 123-152

Aris Angelis, Ansgar Lange and Panos Kanavos

Corruption costs lives: evidence from a cross-country study pp. 153-165

Qiang Li, Lian An, Jing Xu and Mina Baliamoune

Patient preferences: a Trojan horse for evidence-based medicine? pp. 167-172

Afschin Gandjour